F. Hodi

发表

RECIST 1.1-Update and clarification: From the RECIST committee.

Erich P Huang, L. Schwartz, J. Wolchok, 2016, European journal of cancer.

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

J. Fletcher, G. Demetri, F. Hodi, 2008, Clinical Cancer Research.

Major response to imatinib mesylate in KIT-mutated melanoma.

A. D. Van den Abbeele, G. Demetri, F. Hodi, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.

G. Freeman, S. Signoretti, T. Choueiri, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

F. Hodi, F. Hodi, U. Kaiser, 2018, Endocrine reviews.

Improved survival with ipilimumab in patients with metastatic melanoma.

D. Schadendorf, G. Linette, J. Wolchok, 2010, The New England journal of medicine.

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

D. Schadendorf, J. Wolchok, F. Hodi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

H. Kohrt, P. Hegde, R. Herbst, 2014, Nature.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

David C. Smith, J. Taube, M. Atkins, 2012, The New England journal of medicine.

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

C. Paweletz, Guocheng Yuan, P. Jänne, 2016, JCI insight.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J. Lunceford, J. Wolchok, H. Zarour, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

From genes to drugs: targeted strategies for melanoma

K. Flaherty, F. Hodi, D. Fisher, 2012, Nature Reviews Cancer.

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

R. Sullivan, K. Flaherty, M. Atkins, 2014, Cancer.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

A. D. Van den Abbeele, A. Giobbie-Hurder, K. Flaherty, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2014, The Lancet.

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

David M. Woods, M. Vignali, R. Wilson, 2019, Cancer Immunology Research.

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

David C. Smith, A. Drilon, J. Wolchok, 2019, JAMA oncology.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

R. Levy, H. Kohrt, P. Ascierto, 2016, Clinical Cancer Research.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Robert Ford, Otto S Hoekstra, Lawrence H Schwartz, 2017, The Lancet. Oncology.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2019, The New England journal of medicine.

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Benjamin Izar, K. Flaherty, R. Dummer, 2017, Cancer medicine.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Dirk Schadendorf, Reinhard Dummer, Paolo A Ascierto, 2015, The New England journal of medicine.

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

J. Kirkwood, F. Hodi, M. Sznol, 2008 .

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors

P. Jänne, P. Hammerman, A. Bass, 2016, Cancer Immunology Research.

Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab.

F. Hodi, C. Lezcano, J. Luke, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CTLA‐4 to overcome immunological tolerance to melanoma

F. Hodi, 2011 .

Overcoming immunological tolerance to melanoma: Targeting CTLA‐4

F. Hodi, 2010, Asia-Pacific journal of clinical oncology.

Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report.

F. Hodi, S. Granter, J. Antin, 2005, Cancer immunity.

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

J. Wolchok, H. Zarour, A. Ribas, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Response assessment criteria for brain metastases: proposal from the RANO group.

Martin Bendszus, Riccardo Soffietti, Susan M. Chang, 2015, The Lancet. Oncology.

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.

M. Atkins, P. Durani, F. Hodi, 2021, The Lancet. Oncology.

Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non–small cell lung cancer and melanoma brain metastases

P. Catalano, F. Hodi, D. Haas-Kogan, 2020, Cancer.

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

A. Halpern, S. Swetter, M. Ross, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology

J. Wolchok, F. Hodi, A. Hoos, 2015, Clinical Cancer Research.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.

J. Taube, C. Horak, M. Atkins, 2014 .

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

R. Sullivan, K. Flaherty, J. Sosman, 2013 .

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.

J. Wolchok, F. Hodi, P. Ott, 2014 .

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.

David C. Smith, L. Sequist, F. Hodi, 2014 .

Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T-cell therapy.

Stuart A. Sievers, F. Hodi, J. Rossi, 2020, JCI insight.

Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell

D. Neuberg, F. Hodi, S. Ansén, 2007, Clinical Cancer Research.

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

N. Lennon, A. Giobbie-Hurder, R. Mak, 2022, The Lancet. Oncology.

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

A. D. Van den Abbeele, A. Giobbie-Hurder, M. Mihm, 2014, Cancer Immunology Research.

Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.

G. Giaccone, F. Hodi, S. Gettinger, 2017 .

Cancer immunotherapy trials: leading a paradigm shift in drug development

F. Marincola, F. Hodi, L. Butterfield, 2016, Journal of Immunotherapy for Cancer.

F. Hodi, H. Hatabu, M. Nishino, 2015, The New England journal of medicine.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

A. Hauschild, P. Ascierto, R. Dummer, 2016, The New England journal of medicine.

Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)

D. Schadendorf, C. Horak, R. Dummer, 2017 .

Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.

J. Larkin, F. Hodi, G. Schwartz, 2014 .

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

Kristen L. Jones, A. D. Van den Abbeele, Kristen L Jones, 2015, Cancer Immunology Research.

Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients

F. Hodi, N. Ibrahim, P. Ott, 2017, Cancer Immunology Research.

Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study

F. Hodi, L. Molinero, J. Bendell, 2020, Clinical Cancer Research.

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

A. Giobbie-Hurder, G. Freeman, G. Dranoff, 2017, Cancer Immunology Research.

Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes

A. Giobbie-Hurder, M. Shipp, G. Dranoff, 2017, Cancer Immunology Research.

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

R. Jain, Y. Boucher, F. Hodi, 2021, npj Precision Oncology.

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

D. Schadendorf, P. Ascierto, E. Lipson, 2022, The New England journal of medicine.

Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer

P. Jänne, C. Chong, F. Hodi, 2016, Cancer Immunology Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

F. Hodi, H. Hatabu, M. Nishino, 2017, JCO precision oncology.

FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011”

A. Hauschild, K. Flaherty, P. Ascierto, 2012, Journal of Translational Medicine.

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management

F. Hodi, P. Ott, U. Kaiser, 2018, Cancer.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

F. Hodi, H. Kluger, M. Postow, 2017, Journal of immunotherapy.

Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders

G. Pinkus, G. Freeman, F. Hodi, 2016, The American journal of surgical pathology.

Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis

F. Hodi, L. Min, Stephen F. Hodi, 2013, Cancer Immunology Research.

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

J. Lunceford, T. Mcclanahan, M. Ayers, 2015 .

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

J. Wolchok, F. Hodi, Jun Zhou, 2014, Cancer Immunology Research.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

F. Hodi, W. Haining, K. Yates, 2019, Nature Immunology.

The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.

F. Hodi, B. Mahal, B. Alexander, 2019, International journal of radiation oncology, biology, physics.

Melanoma, version 4.2014.

A. Halpern, S. Swetter, M. Ross, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

J. Wolchok, A. Ribas, F. Hodi, 2021, European journal of cancer.

Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma

R. Sullivan, F. Hodi, R. Gonzalez, 2016 .

Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.

M. Atkins, A. Ribas, F. Hodi, 2016 .

Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.

R. Fisher, A. Ribas, F. Hodi, 2016 .

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

J. Wolchok, J. Larkin, F. Hodi, 2015 .

Clinical activity of ipilimumab for metastatic uveal melanoma

A. Giobbie-Hurder, R. Sullivan, K. Flaherty, 2013, Cancer.

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

J. Malvehy, R. Dummer, J. Kirkwood, 2016 .

Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.

J. Wolchok, A. Ribas, F. Hodi, 2014 .

Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort

M. Atkins, A. Ribas, F. Hodi, 2016 .

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

V. Sondak, J. Kirkwood, F. Hodi, 2022, Journal of translational medicine.

Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity

G. Linette, F. Hodi, A. Sober, 2005, Clinical Cancer Research.

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.

O. Cohen, E. V. Van Allen, Catherine J. Wu, 2022, JCO precision oncology.

Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade.

N. Hacohen, B. Ebert, Dennie T. Frederick, 2020, JCO precision oncology.

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

J. Sosman, F. Hodi, S. Gettinger, 2013 .

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

David C. Smith, L. Sequist, F. Hodi, 2014 .

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

J. Taube, E. Lipson, F. Hodi, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytotoxic T-Lymphocyte–Associated Antigen-4

F. Hodi, 2007, Clinical Cancer Research.

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Emily M. Thrash, Emma S. Hathaway, Shuqiang Li, 2021, Blood.

Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients

F. Hodi, F. Hodi, K. Kleinsteuber, 2018, Cell and Tissue Banking.

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

J. Taube, E. Lipson, F. Hodi, 2019 .

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

J. Wolchok, H. Zarour, N. Ibrahim, 2019 .

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

J. Wolchok, T. Powles, F. Hodi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term Overall Survival and Predictors in Anti–PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study

Alistair E. W. Johnson, R. Sullivan, F. Hodi, 2021, Journal of immunotherapy.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

M. Atkins, F. Hodi, H. Tawbi, 2018, The New England journal of medicine.

Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

A. Giobbie-Hurder, F. Hodi, P. Ott, 2014, Clinical Cancer Research.

Melanoma in 2015: Immune-checkpoint blockade — durable cancer control

F. Hodi, E. Buchbinder, 2016, Nature Reviews Clinical Oncology.

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial

A. Giobbie-Hurder, G. Dranoff, J. Ritz, 2017, Clinical Cancer Research.

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab

R. Dummer, F. Hodi, C. Lebbé, 2013, Cancer.

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features

F. Hodi, M. Nishino, M. Severgnini, 2019, Journal of Immunotherapy for Cancer.

Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

J. Wolchok, F. Hodi, P. Ott, 2017 .

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma

P. Ascierto, R. Dummer, J. Wolchok, 2022, Cancers.

VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma

A. Giobbie-Hurder, F. Hodi, S. Rodig, 2016, Cancer Immunology Research.

Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

Jeffrey W. Clark, F. Hodi, M. Sznol, 2010 .

Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma

F. Hodi, D. Fisher, 2008, Nature Clinical Practice Oncology.

Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors

A. Giobbie-Hurder, F. Hodi, F. Hodi, 2021, Cancer Immunology, Immunotherapy.

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

P. Hegde, J. Sosman, F. Hodi, 2019, Clinical Cancer Research.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

K. Morrissey, F. Hodi, M. Ahn, 2019, Clinical Cancer Research.

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

A. Giobbie-Hurder, F. Hodi, P. Ott, 2017, Journal of Immunotherapy for Cancer.

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

T. Choueiri, F. Hodi, P. Ott, 2017, Journal for immunotherapy of cancer.

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

T. Choueiri, F. Hodi, P. Ott, 2017, Journal of Immunotherapy for Cancer.

Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia

A. Egloff, F. Hodi, S. Rodig, 2021, Cancer research communications.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

J. Wolchok, H. Zarour, N. Ibrahim, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.

G. Linette, M. Goldberg, F. Hodi, 2002, Archives of dermatology.

Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis

A. Giobbie-Hurder, R. Sullivan, F. Hodi, 2020, Cancer.

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy

K. Harrington, F. Hodi, I. Puzanov, 2015, Expert review of anticancer therapy.

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma

J. Wolchok, J. Larkin, M. Atkins, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.

V. Sondak, J. Sosman, J. Kirkwood, 2017 .

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Axel Hoos, Jedd D. Wolchok, J. Wolchok, 2009, Clinical Cancer Research.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

James R. Anderson, J. Wolchok, H. Zarour, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to M. Nishino.

J. Wolchok, F. Hodi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

D. Schadendorf, F. Hodi, C. Robert, 2013, Clinical Cancer Research.

Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody

H. Pehamberger, J. Wolchok, F. Hodi, 2008 .

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

F. Hodi, S. O’Day, E. Hersh, 2007 .

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

V. Sondak, J. Kirkwood, F. Hodi, 2022, Quality of Life Research.

Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.

A. Giobbie-Hurder, F. Hodi, P. Ott, 2020, JCO oncology practice.

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor–Related Thyroid Disorders

A. Giobbie-Hurder, F. Hodi, U. Kaiser, 2019, Cancer Immunology Research.

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma

F. Hodi, L. Min, T. Angell, 2017, Genes & diseases.

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

J. Wolchok, M. Atkins, J. Kirkwood, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

G. Linette, C. Horak, J. Wolchok, 2017 .

The use of granulocyte-macrophage colony-stimulating factor in melanoma treatment.

F. Hodi, 2015, Clinical advances in hematology & oncology : H&O.

Therapeutic Discovery Protein Kinase C Inhibitor AEB 071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC / Erk 1 / 2 and PKC / NFk B Pathways

J. Fletcher, F. Hodi, Meijun Zhu, 2012 .

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

S. Haferkamp, R. Dummer, J. Kirkwood, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunologic profiling of adenoid cystic carcinoma (acc)

G. Freeman, G. Dranoff, F. Hodi, 2015, Journal of Immunotherapy for Cancer.

Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma

Jeffrey W. Clark, F. Hodi, D. Finkelstein, 2002, American journal of clinical oncology.

Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2015 .

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.

N. Schultz, M. Berger, L. Macconaill, 2022, Cancer cell.

1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

James R. Anderson, J. Kirkwood, A. Ribas, 2021, Annals of Oncology.

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2015, Journal of Translational Medicine.

Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

J. Wolchok, A. Ribas, F. Hodi, 2014 .

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of Clinical Oncology.

Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.

G. Demetri, F. Hodi, G. Shapiro, 2016 .

Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients.

L. Garraway, C. Horak, T. Choueiri, 2017 .

Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.

M. Atkins, F. Hodi, H. Tawbi, 2017 .

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

M. Atkins, F. Hodi, H. Tawbi, 2019, Journal of Clinical Oncology.

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

D. Schadendorf, R. Dummer, J. Wolchok, 2022, Journal of Clinical Oncology.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma, version 2.2016 clinical practice guidelines in oncology

A. Halpern, S. Swetter, M. Ross, 2016 .

Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis

F. Hodi, D. Wong, O. Rahma, 2021, Hepatology.

Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event

F. Hodi, H. Hatabu, M. Nishino, 2018, Cancer Immunology Research.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

G. Linette, C. Horak, J. Wolchok, 2015, The New England journal of medicine.

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

M. Atkins, F. Hodi, M. Smylie, 2020, Melanoma research.

PD‐1 inhibitor‐related pneumonitis in lymphoma patients treated with single‐agent pembrolizumab therapy

F. Hodi, H. Hatabu, M. Nishino, 2018, British journal of haematology.

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

P. Ascierto, E. Lipson, F. Hodi, 2017 .

Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity

A. Giobbie-Hurder, T. Sittler, G. Dranoff, 2008, Clinical Cancer Research.

Treatment for advanced melanoma: new drugs, new opportunities, new challenges.

F. Hodi, P. Ott, 2013, Oncology.

Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab

C. Horak, F. Hodi, D. Woods, 2016 .

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

J. Taube, C. Horak, M. Atkins, 2016 .

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

G. Linette, F. Hodi, S. D'Angelo, 2014 .

Improved Endpoints for Cancer Immunotherapy Trials

Sylvia Janetzki, Axel Hoos, J. Wolchok, 2010, Journal of the National Cancer Institute.

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

M. Atkins, F. Hodi, H. Tawbi, 2021, Neuro-oncology.

The role of whole brain radiation therapy in the management of melanoma brain metastases

F. Hodi, E. Lee, B. Alexander, 2014, Radiation Oncology.

Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma.

J. Wolchok, F. Hodi, J. Haanen, 2010 .

When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

L. Schwartz, M. Kris, M. Morris, 2012, Journal of the National Cancer Institute.

An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

K. Flaherty, J. Wolchok, F. Hodi, 2016, Clinical Cancer Research.

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

F. Hodi, Y. Bang, P. LoRusso, 2019, Journal of Clinical Oncology.

Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2015 .

Risk of Bias and Heterogeneity-Reply.

A. Giobbie-Hurder, F. Hodi, M. Nishino, 2017, JAMA oncology.

1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2017 .

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

J. Malvehy, R. Dummer, J. Kirkwood, 2015, Journal of Immunotherapy for Cancer.

The n e w e n g l a n d j o u r n a l of m e d i c i n e Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

D. Schadendorf, G. Linette, J. Wolchok, 2022 .

A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2014 .

A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2013 .

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

J. Wolchok, H. Zarour, A. Ribas, 2015 .

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES

J. Wolchok, H. Zarour, A. Ribas, 2014 .

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.

J. Wolchok, J. Larkin, F. Hodi, 2019, Journal of Clinical Oncology.

Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results.

J. Wolchok, F. Hodi, M. Sznol, 2012 .

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge

F. Hodi, B. Alexander, P. Ott, 2016, Journal of Neuro-Oncology.

Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).

J. Wolchok, A. Ribas, F. Hodi, 2014 .

Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.

D. Leaf, F. Hodi, P. Ott, 2020, Kidney international.

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.

D. Leaf, M. Troxell, J. Wolchok, 2016, Kidney international.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

KIT Gene Mutations and Copy Number in Melanoma Subtypes

Susan Muller, Janice Patterson, R. West, 2008, Clinical Cancer Research.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

13 – Skin Cancer

M. Wick, F. Hodi, P. Friedlander, 2010 .

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

N. Popitsch, H. Kohrt, R. Sullivan, 2013, Clinical Cancer Research.

Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas

M. Mihm, C. Lian, F. Hodi, 2015, Clinical Epigenetics.

Melanoma, version 2.2013: featured updates to the NCCN guidelines.

A. Halpern, S. Swetter, M. Ross, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

J. Larkin, F. Hodi, D. Reardon, 2017, The oncologist.

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

R. Sullivan, F. Hodi, H. Tawbi, 2019, Nature Medicine.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

D. Schadendorf, R. Dummer, J. Wolchok, 2018, The Lancet. Oncology.

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

R. Sullivan, K. Flaherty, Dennie T. Frederick, 2013, Clinical Cancer Research.

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

A. Giobbie-Hurder, J. Wargo, F. Hodi, 2012, Clinical Cancer Research.

Association of PD-L2 expression in human tumors with atezolizumab activity.

P. Hegde, T. Powles, F. Hodi, 2016 .

Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

F. Hodi, Y. Bang, H. Joensuu, 2018 .

Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.

F. Hodi, S. Hu-Lieskovan, J. Brody, 2021, European journal of cancer.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Robert E. Jones, Gordon J. Freeman, 2016, Nature Communications.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

M. Atkins, A. Ribas, F. Hodi, 2017, The Lancet. Oncology.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

K. Savage, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

G. Linette, C. Horak, J. Wolchok, 2016, The Lancet. Oncology.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

C. Horak, R. Sullivan, J. Sosman, 2016, The Lancet. Oncology.

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

D. Schadendorf, D. Jackson, P. Ascierto, 2021, Cancer Immunology Research.

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

T. Choueiri, G. Sonpavde, F. Hodi, 2021, Clinical Cancer Research.

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma

P. Catalano, G. Freeman, Catherine J. Wu, 2020, Clinical Cancer Research.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

D. Jackson, A. Giobbie-Hurder, C. Horak, 2018, Science Translational Medicine.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Mark W. Ball, C. Horak, E. V. Van Allen, 2018, Science.

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

F. Hodi, H. Hatabu, M. Nishino, 2017, Nature Reviews Clinical Oncology.

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

D. Schadendorf, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Suzanne F. Jones, Fabien Gaire, P. Hegde, 2016, Nature Communications.

Molecular genetics of familial cutaneous melanoma.

F. Hodi, F. Haluska, F. Hodi, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

A. Giobbie-Hurder, C. Antonescu, R. Sullivan, 2015, Clinical Cancer Research.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2017, European journal of cancer.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

David C. Smith, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Zhi Wei, Hongye Liu, Wei Huang, 2018, Cancer discovery.

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

D. Neuberg, M. Shipp, G. Freeman, 2017, Blood.

Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies

F. Hodi, A. Dobry, P. Ott, 2018, Cancer Immunology, Immunotherapy.

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

A. Giobbie-Hurder, F. Hodi, S. Rodig, 2016, Cancer Immunology Research.

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

E. Winer, E. V. Van Allen, L. Macconaill, 2020, Clinical Cancer Research.

Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors

X. Liu, E. V. Van Allen, S. Signoretti, 2020, Cancer Immunology Research.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

V. Sondak, R. Sullivan, M. Atkins, 2018, Journal of Immunotherapy for Cancer.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

G. Getz, D. Schadendorf, B. Schilling, 2018, Nature Genetics.

Combination immunotherapy: a road map

J. Wolchok, F. Hodi, P. Ott, 2017, Journal of Immunotherapy for Cancer.

Talimogene Laherparepvec for the Treatment of Advanced Melanoma

F. Hodi, P. Ott, 2016, Clinical Cancer Research.

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Jing Wang, G. Freeman, I. Wistuba, 2016, Cancer research.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

P. Jänne, G. Freeman, F. Hodi, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.

R. Jain, L. Coussens, F. Hodi, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

David C. Smith, J. Taube, M. Atkins, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Katie M. Campbell, V. Velculescu, P. Ross-Macdonald, 2020, Cancer cell.

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade

A. Giobbie-Hurder, F. Hodi, P. Ott, 2021, Cancer medicine.

Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy.

Kristen L Jones, K. Ligon, G. Freeman, 2014 .

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Michael E. Lassman, J. Malvehy, R. Dummer, 2017, Cell.

KIT as a Therapeutic Target for Melanoma

F. Hodi, N. Ibrahim, 2012 .

PD-L1 expression in nonclear-cell renal cell carcinoma.

G. Freeman, S. Signoretti, T. Ho, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumour CD274 (PD-L1) expression and T cells in colorectal cancer

Mingyang Song, Yin Cao, Reiko Nishihara, 2016, Gut.

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

P. Catalano, C. Horak, G. Freeman, 2019, Clinical Cancer Research.

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

G. Freeman, S. Signoretti, F. Hodi, 2015, Cancer Immunology Research.

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

D. Schadendorf, A. Giobbie-Hurder, E. V. Van Allen, 2022, bioRxiv.

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation

S. Carter, L. Garraway, E. V. Van Allen, 2015, Cancer Immunology Research.

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

G. Freeman, Su-Chun Cheng, S. Signoretti, 2015, Cancer Immunology Research.

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

E. Cerami, I. Wistuba, Catherine J. Wu, 2021, Clinical Cancer Research.

Melanoma Immunology and Immunotherapy

R. Sullivan, F. Hodi, 2019, Melanoma.

Introduction to Melanoma Immunology

R. Sullivan, F. Hodi, 2019, Melanoma.

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

J. Wolchok, F. Hodi, M. Sznol, 2012, The Lancet. Oncology.

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

David C. Smith, M. Atkins, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatotoxicity with combination of vemurafenib and ipilimumab.

J. Wolchok, A. Ribas, F. Hodi, 2013, The New England journal of medicine.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

David C. Smith, J. Sosman, L. Sequist, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

Yan Shi, G. Freeman, A. Bass, 2017, Cancer Immunology Research.

Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

A. Giobbie-Hurder, F. Hodi, H. Hatabu, 2016, JAMA oncology.

Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.

A. LaCasce, D. Neuberg, M. Shipp, 2020, Blood.

Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.

G. Linette, C. Horak, J. Wolchok, 2015 .

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

J. Sosman, R. Herbst, F. Hodi, 2013 .

Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade.

Clifford A. Meyer, Henry W. Long, X. Liu, 2021, Cancer discovery.

Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation.

P. Catalano, F. Hodi, B. Alexander, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.

F. Hodi, P. Ott, A. Spektor, 2017, International journal of radiation oncology, biology, physics.

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know

F. Hodi, S. Tirumani, M. Nishino, 2017, Korean journal of radiology.

PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

F. Hodi, H. Hatabu, P. Ott, 2016, Clinical Cancer Research.

Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.

D. Neuberg, M. Shipp, G. Freeman, 2016, JAMA oncology.

Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.

F. Hodi, S. Tirumani, M. Nishino, 2015, European journal of radiology.

Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity

C. Lian, F. Hodi, S. Rodig, 2017, Laboratory Investigation.

Combinatorial cancer immunotherapy.

F. Hodi, G. Dranoff, F. Hodi, 2006, Advances in immunology.

Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.

T. Choueiri, M. Atkins, A. Ribas, 2017 .

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.

F. Hodi, H. Hatabu, M. Nishino, 2019, Radiology.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

D. Schadendorf, R. Dummer, J. Wolchok, 2017, JAMA oncology.

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

D. Schadendorf, R. Dummer, J. Wolchok, 2021 .

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

D. Schadendorf, P. Ascierto, E. Lipson, 2021 .

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Robert Ford, Otto S Hoekstra, Yan Liu, 2016, European journal of cancer.

Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071

Niladri Roy Chowdhury, C. Emery, J. Larkin, 2020, Molecular Cancer Therapeutics.

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

F. Hodi, G. Curigliano, A. Santoro, 2021, Clinical Cancer Research.

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

F. Hodi, S. O’Day, T. Guthrie, 2016, Journal of Immunotherapy for Cancer.

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.

F. Hodi, E. Buchbinder, 2015, The Journal of clinical investigation.

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

F. Hodi, M. Nishino, N. Ramaiya, 2014, Journal of Immunotherapy for Cancer.

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

V. Sondak, M. Atkins, J. Sosman, 2013, Nature Reviews Clinical Oncology.

Annals of the New York Academy of Sciences Development of Ipilimumab: a Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma

J. Wolchok, F. Hodi, J. Allison, 2022 .

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

A. Giobbie-Hurder, F. Hodi, M. Nishino, 2013, Clinical Cancer Research.

Ipilimumab for patients with advanced mucosal melanoma.

R. Sullivan, K. Flaherty, J. Wolchok, 2013, The oncologist.

Ipilimumab and its toxicities: a multidisciplinary approach.

F. Hodi, L. Fecher, J. Weber, 2013, The oncologist.

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

F. Hodi, J. Luke, Jason J. Luke, 2013, The oncologist.

Cytotoxic T-Lymphocyte–Associated Antigen-4

F. Hodi, A. Salama, S. Hodi, 2007, Clinical Cancer Research.

Molecular Pathways Cytotoxic T-Lymphocyte – Associated Antigen-4 April

F. Hodi, K. S. Salama, 2011 .

Characterization of the Neuroendocrine Tumor Immune Microenvironment

F. Hodi, A. Thorner, F. Hodi, 2018, Pancreas.

NCCN Melanoma Clinical Practice Guidelines in Oncology

A. Halpern, S. Swetter, M. Ross, 2012 .

Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm.

F. Hodi, A. Zembowicz, John F. Thompson, 2007, The New England journal of medicine.

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

G. Freeman, K. Flaherty, Dennie T. Frederick, 2014, Cancer Immunology Research.

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

F. Hodi, P. Ott, E. Buchbinder, 2015, Front. Oncol..

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

J. Kirkwood, F. Hodi, L. Butterfield, 2014, JAMA.

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

J. Wolchok, F. Hodi, C. Balch, 2014, Cancer treatment reviews.

High cycle fatigue of weld repaired cast Ti-6AI-4V

Thomas W. Eagar, Gordon B. Hunter, F. Hodi, 1982 .

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma

A. Giobbie-Hurder, F. Hodi, D. Fisher, 2016, Cancer medicine.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

J. Wolchok, J. Larkin, F. Hodi, 2015, The New England journal of medicine.

TheActivation ofMAPK inMelanomaCells Resistant toBRAF Inhibition Promotes PD-L 1 Expression That Is Reversible by MEK and PI 3 K Inhibition

A. Giobbie-Hurder, J. Wargo, F. Hodi, 2013 .

Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.

K. Flaherty, F. Hodi, N. LeBoeuf, 2012, Archives of dermatology.

Cell metastasis in Melanoma

F. Hodi, P. Ott, 2012 .

Mutation-driven drug development in melanoma

K. Flaherty, F. Hodi, B. Bastian, 2010, Current opinion in oncology.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

C. Berking, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials

P. Ascierto, J. Larkin, F. Hodi, 2021, Melanoma research.

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Toshio Shimizu, F. Hodi, M. Hellmann, 2021, Clinical Cancer Research.

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

R. Dummer, J. Wolchok, A. Ribas, 2020, European journal of cancer.

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

M. Atkins, A. Ribas, F. Hodi, 2020, Clinical Cancer Research.

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST

L. Schwartz, K. Harrington, F. Hodi, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Eudocia Q Lee, Martin Bendszus, Gordon J Harris, 2018, The Lancet. Oncology.

Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

F. Hodi, S. Hodi, Daniel S. Chen, 2012, Clinical Cancer Research.

Advances in targeted therapy for melanoma.

F. Hodi, P. Friedlander, 2010, Clinical advances in hematology & oncology : H&O.

Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma: Cancer and Leukemia Group B 509901

John D Roberts, Donna Niedzwiecki, Alan Houghton, 2006, Journal of immunotherapy.

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis

W. Barry, F. Hodi, R. Barroso-Sousa, 2017, JAMA oncology.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

T. Choueiri, G. Sonpavde, F. Hodi, 2017, Cancer Immunology Research.

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

A. Giobbie-Hurder, F. Hodi, M. Nishino, 2014, Journal of Immunotherapy for Cancer.

Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.

A. Giobbie-Hurder, Helen X. Chen, F. Hodi, 2019, Journal of Clinical Oncology.

P. Jänne, F. Hodi, H. Hatabu, 2016, Journal of Immunotherapy for Cancer.

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).

J. Sosman, F. Hodi, M. Sznol, 2012 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

D. Schadendorf, C. Horak, R. Dummer, 2016 .

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study

G. Freeman, S. Signoretti, F. Hodi, 2015, Journal of Immunotherapy for Cancer.

Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome

P. Jänne, F. Hodi, H. Hatabu, 2017, Clinical Cancer Research.

A. Giobbie-Hurder, F. Hodi, P. Ott, 2017, Clinical Cancer Research.

Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ”

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

Immune-Modi fi ed Response Evaluation Criteria In Solid Tumors ( imRECIST ) : Re fi ning Guidelines to Assess the Clinical Bene fi t of Cancer Immunotherapy

J. Wolchok, T. Powles, F. Hodi, 2018 .

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

G. Linette, J. Sosman, J. Kirkwood, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2016, JAMA.

Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course

A. Giobbie-Hurder, F. Hodi, N. LeBoeuf, 2022, Cancer.

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Hussein Tawbi, Aliya N. Husain, L. Heinzerling, 2016, Journal of Immunotherapy for Cancer.

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

A. Giobbie-Hurder, F. Hodi, P. Ott, 2017, Cancer Immunology Research.

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab

F. Hodi, S. Tirumani, P. Ott, 2015, Cancer Immunology Research.

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

G. Linette, J. Hainsworth, K. Flaherty, 2014, Cancer journal.

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2013, The Lancet. Oncology.

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

M. Mihm, A. Day, F. Hodi, 2008, Nature Clinical Practice Oncology.

Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma

G. Linette, J. Sosman, F. Hodi, 2007 .

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

F. Hodi, F. Hodi, G. Shapiro, 2017, Cancer.

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

D. Neuberg, M. Mihm, G. Dranoff, 2008, Proceedings of the National Academy of Sciences.

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2013, The Lancet. Oncology.

5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.

J. Wolchok, H. Zarour, A. Ribas, 2018 .

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

D. Schadendorf, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2016 .

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.

A. Giobbie-Hurder, R. Sullivan, K. Flaherty, 2015, The oncologist.

Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma

A. Giobbie-Hurder, A. Iafrate, R. Sullivan, 2014, Molecular Cancer Therapeutics.

Clinical Utility of a Blood-Based BRAFMutation Assay in Melanoma

A. Iafrate, R. Sullivan, K. Flaherty, 2014 .

Companion Diagnostics and Cancer Biomarkers Clinical Utility of a Blood-Based BRAFV 600 EMutation Assay in Melanoma

A. Giobbie-Hurder, A. Iafrate, R. Sullivan, 2014 .

Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines

A. Halpern, S. Swetter, M. Ross, 2013 .

D. Schadendorf, A. Abernethy, R. Dummer, 2017, European journal of cancer.

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute

F. Hodi, A. Sober, F. Haluska, 2005, Melanoma research.

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma

A. D. Van den Abbeele, A. Giobbie-Hurder, G. Linette, 2015, Cancer.

Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

K. Ligon, F. Hodi, D. Reardon, 2018, Cancer Immunology Research.

CheckMate 067: Long-term outcomes in patients with mucosal melanoma.

P. Ascierto, R. Dummer, J. Larkin, 2020 .

Melanoma Brain Metastases Treated With Brain-directed Radiation Followed by Ipilimumab

I. Kaplan, R. Sullivan, F. Hodi, 2012 .

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J. Wolchok, A. Ribas, F. Hodi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

J. Wolchok, A. Ribas, F. Hodi, 2018 .

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade

B. Ebert, W. Wong, F. Hodi, 2020, Haematologica.

Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

T. Choueiri, F. Hodi, G. De Velasco, 2015, Cancer Immunology Research.

Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry

F. Hodi, F. Hodi, Emily Mcwilliams, 2019, Journal of biological methods.

Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma

Charles H. Yoon, A. Giobbie-Hurder, F. Hodi, 2014, Cancer Immunology Research.

Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma

A. Giobbie-Hurder, F. Hodi, Jun Zhou, 2011, Cancer Immunology, Immunotherapy.

Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma

J. Sosman, F. Hodi, Douglas B. Johnson, 2017, Cancer Immunology Research.

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

G. Giaccone, F. Hodi, S. Gettinger, 2018, European journal of cancer.

A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).

J. Malvehy, R. Dummer, J. Kirkwood, 2016 .

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.

F. Hodi, Y. Bang, L. Chow, 2021, The Lancet. Oncology.

Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on Stage

F. Hodi, Stephen F. Hodi, 2006, Clinical Cancer Research.

Well-DefinedMelanoma Antigens as ProgressionMarkers for Melanoma : Insights into Differential Expression and Host Response Based on Stage 55 Commentary on Barrow et al . p . 764

F. Hodi, 2006 .

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

V. Sondak, J. Sosman, J. Kirkwood, 2021, Journal for ImmunoTherapy of Cancer.

648 Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors

A. Giobbie-Hurder, F. Hodi, P. Ott, 2020 .

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

A. Ng, F. Hodi, B. Alexander, 2015, Oncoimmunology.

Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

David C. Smith, J. Taube, M. Atkins, 2013 .

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013

B. Schilling, F. Marincola, R. Sullivan, 2014, Journal of Translational Medicine.

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

A. Giobbie-Hurder, F. Hodi, P. Ott, 2015, Cancer Immunology Research.

Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis

F. Hodi, D. Wong, O. Rahma, 2021, Hepatology.

Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

G. Linette, J. Wolchok, F. Hodi, 2016 .

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Michael E. Lassman, J. Malvehy, R. Dummer, 2017, Cell.

T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer

F. Hodi, P. Ott, 2015 .

The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.

F. Hodi, P. Ott, 2012, Chinese clinical oncology.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

D. Schadendorf, B. Schilling, P. Jänne, 2018, Nature Genetics.

Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.

K. Flaherty, R. Dummer, M. Atkins, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT176: Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors

J. Kirkwood, F. Hodi, G. Gibney, 2018, Clinical Trials.

Response toBRAF Inhibition inMelanoma Is EnhancedWhen Combined with Immune Checkpoint Blockade

G. Freeman, K. Flaherty, Dennie T. Frederick, 2014 .

Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma

F. Hodi, J. Luke, S. Hodi, 2011, Clinical Cancer Research.

Abstract LB-223: ATLASTMreveals a dominant inhibitory antigen in melanoma patients, and a reduced breadth of tumor-associated antigen-specific T cells in non-responders to checkpoint blockade

Christopher L. Warren, James J Foti, F. Hodi, 2019, Clinical Research (Excluding Clinical Trials).

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

A. D. Van den Abbeele, A. Giobbie-Hurder, F. Hodi, 2014, Cancer Imaging.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma

A. Giobbie-Hurder, R. Sullivan, K. Flaherty, 2018, Melanoma research.

Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

D. Schadendorf, C. Horak, R. Dummer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

D. Schadendorf, R. Dummer, J. Wolchok, 2019, Annals of Oncology.

1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma

R. Fisher, A. Ribas, F. Hodi, 2017 .

Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.

R. Sullivan, F. Hodi, P. Hwu, 2017 .

Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization

C. Paweletz, P. Jänne, F. Hodi, 2018, Melanoma research.

Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.

F. Hodi, O. Hamid, J. Weber, 2021 .

Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Jedd D. Wolchok, Antoni Ribas, Richard F. Kefford, 2016 .

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

A. Giobbie-Hurder, F. Hodi, H. Maecker, 2018, Journal of Immunotherapy for Cancer.

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

V. Sondak, J. Kirkwood, F. Hodi, 2022, Quality of Life Research.

Prolonged survival in objective responders to ipilimumab therapy

F. Hodi, S. O’Day, E. Hersh, 2008 .

The Intersection between Tumor Angiogenesis and Immune Suppression

F. Hodi, O. Rahma, Stephen F. Hodi, 2019, Clinical Cancer Research.

ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.

F. Hodi, J. Schellens, D. Kaufman, 2016 .

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

K. Morrissey, F. Hodi, P. LoRusso, 2017 .

Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.

F. Hodi, J. Jagannathan, N. Ramaiya, 2011, AJR. American journal of roentgenology.

Abstract A83: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

F. Hodi, F. Hodi, W. Haining, 2020, Poster Presentations - Proffered Abstracts.

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas.

F. Hodi, F. Meric-Bernstam, W. Messersmith, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Early Palliative Care in Non-Small-Cell Lung Cancer

F. Hodi, S. O’Day, 2021, 50 Studies Every Doctor Should Know.

Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. Reply.

F. Hodi, H. Tawbi, G. Long, 2022, The New England journal of medicine.

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

T. Choueiri, M. Atkins, A. Ribas, 2018, Clinical Cancer Research.

Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study.

F. Hodi, P. Ott, H. Kaufman, 2014 .

1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2020 .

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

F. Hodi, Y. Bang, M. Sznol, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

J. Wolchok, H. Zarour, A. Ribas, 2014, Journal of Immunotherapy for Cancer.

PD-L 1 expression in nonclear-cell renal cell carcinoma

G. Freeman, S. Signoretti, T. Ho, 2014 .

Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma

D. Schadendorf, D. Jackson, P. Ascierto, 2019, Clinical Trials.

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Katie M. Campbell, V. Velculescu, P. Ross-Macdonald, 2020, Cancer cell.

Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))

Michael E. Lassman, J. Malvehy, R. Dummer, 2018 .

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.

Daniel K. Wells, J. Wolchok, J. Larkin, 2023, Cancer cell.

136P Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors

F. Hodi, H. Prenen, V. Stalbovskaya, 2021, Annals of Oncology.

Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).

T. Choueiri, M. Atkins, A. Ribas, 2016 .

Landscape of genetic alterations in patients with metastatic uveal melanoma.

C. Emery, J. Larkin, A. Derti, 2014 .

Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes.

R. Sullivan, K. Flaherty, C. Sadow, 2016 .

The role of whole brain radiation therapy in the management of melanoma brain metastases

F. Hodi, E. Lee, N. Ibrahim, 2014, Radiation Oncology.

A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

J. Sosman, F. Hodi, J. Haanen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis

F. Hodi, O. Rahma, S. Zucker, 2020, Cancer.

1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

R. Sullivan, F. Hodi, O. Hamid, 2021, Annals of Oncology.

A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma.

A. D. Van den Abbeele, A. Giobbie-Hurder, M. Atkins, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors.

F. Hodi, G. Gibney, N. Rizvi, 2013 .

Genetically distinct cell populations in naturally occurring bone marrow-chimeric primates express similar MHC class I gene products.

A. Hughes, D. Watkins, N. Letvin, 1990, Journal of immunology.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.

V. Sondak, J. Kirkwood, F. Hodi, 2020 .

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

J. Wolchok, F. Hodi, G. Gibney, 2016 .

Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis

F. Hodi, S. Grover, Matthew J. Townsend, 2023, ACG case reports journal.

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067).

D. Schadendorf, R. Dummer, J. Wolchok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.

A. Giobbie-Hurder, R. Sullivan, K. Flaherty, 2012 .

Corticosteroids and immune checkpoint blockade

F. Hodi, U. Kaiser, L. Min, 2015, Aging.

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

P. Catalano, G. Freeman, Catherine J. Wu, 2020 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012 .

A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.

A. Giobbie-Hurder, R. Sullivan, F. Hodi, 2020, Journal of Clinical Oncology.

Targeted therapeutics in melanoma

F. Hodi, T. Gajewski, 2012 .

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

J. Malvehy, R. Dummer, J. Kirkwood, 2015 .

A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

F. Hodi, T. Guthrie, A. Salama, 2015 .

Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases.

F. Hodi, J. Thompson, A. Pavlick, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

D. Schadendorf, C. Horak, P. Ascierto, 2016 .

Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.

F. Hodi, P. Ott, S. Rodig, 2021 .

Impact of Precision Medicine in Oncology

F. Hodi, E. Buchbinder, 2023, Cancer journal.

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

F. Hodi, G. Fine, O. Hamid, 2013 .

A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

H. Kohrt, J. Wolchok, F. Hodi, 2013 .

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

D. Schadendorf, P. Ascierto, E. Lipson, 2022, Journal of Clinical Oncology.

Reply to T. Olivier et al.

J. Wolchok, F. Hodi, J. Larkin, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma

J. Larkin, J. Kirkwood, F. Hodi, 2023, Frontiers in Oncology.

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2015, Journal of Translational Medicine.

CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma.

J. Wolchok, A. Ribas, F. Hodi, 2012 .

A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.

R. Dummer, J. Kirkwood, A. Ribas, 2015 .

Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.

G. Linette, M. Mihm, M. Gadd, 2000, Cancer journal.

Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.

Andrew J. Park, J. Wolchok, F. Hodi, 2015 .

Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.

T. Choueiri, M. Atkins, A. Ribas, 2015 .

A plea for prices in physician prescribing.

F. Hodi, M. Reidenberg, 1991, JAMA.

PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma.

G. Freeman, S. Signoretti, T. Choueiri, 2014 .

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Network Boston.

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .

Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2013 .

Future Perspectives in melanoma research. Meeting report from the Research: a to

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

Cytotoxic T-Lymphocyte–Associated Antigen-4

F. Hodi, 2007, Clinical Cancer Research.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.

F. Hodi, S. Gettinger, T. Mok, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma

F. Hodi, N. Ibrahim, Jennifer Y. Lin, 2016, Oncotarget.

1222PDRegional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

D. Schadendorf, P. Ascierto, J. Wolchok, 2017 .

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

D. Schadendorf, P. Ascierto, E. Lipson, 2023, Journal of Clinical Oncology.

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.

D. Schadendorf, P. Ascierto, E. Lipson, 2023, Journal of Clinical Oncology.

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

C. Horak, R. Sullivan, J. Sosman, 2015 .

Ipilimumab (IPI) Expanded Access Program (EAP) for Patients (PTS) with Stage III/IV Melanoma: Safety Data by Subgroups

J. Wolchok, F. Hodi, D. Lawrence, 2012 .

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients

F. Hodi, K. Kleinsteuber, Jun Zhou, 2018, Cell and Tissue Banking.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Integrated molecular drivers coordinate biological and clinical states in melanoma

D. Schadendorf, B. Schilling, E. V. Van Allen, 2020, Nature Genetics.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

A. D. Van den Abbeele, A. Giobbie-Hurder, M. Mihm, 2014, Cancer Immunology Research.

Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay.

K. Flaherty, M. Atkins, F. Hodi, 2012 .

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

P. Ascierto, F. Hodi, M. Sznol, 2015, Journal of Immunotherapy for Cancer.

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Jing Wang, I. Wistuba, P. Hammerman, 2016, Cancer research.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

F. Hodi, W. Haining, K. Yates, 2019, Nature Immunology.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Monika S. Kowalczyk, A. Regev, P. Sorger, 2018, Cell.

Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

A. Giobbie-Hurder, F. Hodi, P. Ott, 2014, Clinical Cancer Research.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

P. Jänne, F. Hodi, D. Jackman, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

A. Giobbie-Hurder, F. Hodi, S. Rodig, 2016, Cancer Immunology Research.

Major response to imatinib mesylate in KIT-mutated melanoma.

A. D. Van den Abbeele, G. Demetri, F. Hodi, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

F. Hodi, P. Ott, C. Robert, 2013, Clinical Cancer Research.

The role of whole brain radiation therapy in the management of melanoma brain metastases

F. Hodi, E. Lee, B. Alexander, 2014, Radiation Oncology.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

G. Giaccone, F. Hodi, S. Gettinger, 2015 .